Literature DB >> 11873924

Early Toronto experience with new standards for industry-sponsored clinical research: a progress report.

C David Naylor1.   

Abstract

Keywords:  Biomedical and Behavioral Research; Hospital for Sick Children (Toronto); University of Toronto

Mesh：

Year:  2002        PMID： 11873924      PMCID： PMC99356     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  13 in total

1.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.

Authors:  H K Johansen; P C Gotzsche
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

2.  Sponsorship, authorship, and accountability.

Authors:  F Davidoff; C D DeAngelis; J M Drazen; J Hoey; L Højgaard; R Horton; S Kotzin; M G Nicholls; M Nylenna; A J Overbeke; H C Sox; M B Van Der Weyden; M S Wilkes
Journal:  JAMA       Date:  2001-09-12       Impact factor: 56.272

Review 3.  Industry-sponsored clinical research: a double-edged sword.

Authors:  J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

4.  Industry-sponsored research.

Authors:  M Kiln
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

5.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  Publishing sensitive data: who calls the shots? Secrecy dispute pits Brown researcher against company.

Authors:  W Roush
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

7.  Thyroid storm.

Authors:  D Rennie
Journal:  JAMA       Date:  1997-04-16       Impact factor: 56.272

8.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis.

Authors:  P A Rochon; J H Gurwitz; R W Simms; P R Fortin; D T Felson; K L Minaker; T C Chalmers
Journal:  Arch Intern Med       Date:  1994-01-24

9.  Redundancy, disaggregation, and the integrity of medical research.

Authors:  P Huston; D Moher
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

10.  Should there be early publication of ancillary studies prior to the first primary report of an unblinded randomized clinical trial?

Authors:  D L Sackett; C D Naylor
Journal:  J Clin Epidemiol       Date:  1993-04       Impact factor: 6.437
View more
  12 in total

1.  The deferiprone controversy: time to move on.

Authors:  C David Naylor
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

2.  Questions of interest.

Authors: 
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

3.  Getting it right: industry sponsorship and medical research.

Authors:  Patricia Baird
Journal:  CMAJ       Date:  2003-05-13       Impact factor: 8.262

4.  The Olivieri Report--a compelling study of the growing tensions in clinical research.

Authors:  Vincent di Norcia
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

5.  Better governance in academic health sciences centres: moving beyond the Olivieri/Apotex Affair in Toronto.

Authors:  L E Ferris; P A Singer; C D Naylor
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

6.  Assessing the bioethical integrity of a clinical trial in surgery.

Authors:  Mark Bernstein
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

7.  Institutional ethics review of clinical study agreements.

Authors:  G DuVal
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

8.  National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers.

Authors:  Joel Lexchin; Melanie Sekeres; Jennifer Gold; Lorraine E Ferris; Sunila R Kalkar; Wei Wu; Marleen Van Laethem; An-Wen Chan; David Moher; M James Maskalyk; Nathan Taback; Paula A Rochon
Journal:  J Gen Intern Med       Date:  2008-08-21       Impact factor: 5.128

9.  Investigator experiences with financial conflicts of interest in clinical trials.

Authors:  Paula A Rochon; Melanie Sekeres; John Hoey; Joel Lexchin; Lorraine E Ferris; David Moher; Wei Wu; Sunila R Kalkar; Marleen Van Laethem; Andrea Gruneir; Jennifer Gold; James Maskalyk; David L Streiner; Nathan Taback; An-Wen Chan
Journal:  Trials       Date:  2011-01-12       Impact factor: 2.279

10.  Too few, too weak: conflict of interest policies at Canadian medical schools.

Authors:  Adrienne Shnier; Joel Lexchin; Barbara Mintzes; Annemarie Jutel; Kelly Holloway
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.